HK1252514A1 - 包含與抗體組合施予的ido抑制劑的腫瘤治療劑 - Google Patents
包含與抗體組合施予的ido抑制劑的腫瘤治療劑Info
- Publication number
- HK1252514A1 HK1252514A1 HK18111823.0A HK18111823A HK1252514A1 HK 1252514 A1 HK1252514 A1 HK 1252514A1 HK 18111823 A HK18111823 A HK 18111823A HK 1252514 A1 HK1252514 A1 HK 1252514A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tumor
- antibody
- combination
- therapeutic agent
- ido inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562192173P | 2015-07-14 | 2015-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1252514A1 true HK1252514A1 (zh) | 2019-05-31 |
Family
ID=57757291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18111823.0A HK1252514A1 (zh) | 2015-07-14 | 2018-09-14 | 包含與抗體組合施予的ido抑制劑的腫瘤治療劑 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180271861A1 (zh) |
EP (2) | EP3322444A4 (zh) |
JP (2) | JP2018524361A (zh) |
KR (1) | KR20180025897A (zh) |
CN (1) | CN107847597A (zh) |
AU (1) | AU2016293667A1 (zh) |
CA (1) | CA2992238A1 (zh) |
HK (1) | HK1252514A1 (zh) |
TW (1) | TW201713332A (zh) |
WO (1) | WO2017010106A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3658185A4 (en) | 2017-07-28 | 2021-07-14 | Phanes Therapeutics, Inc. | ANTI-TIM-3 ANTIBODIES AND USES THEREOF |
US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
CN112961239B (zh) * | 2021-02-24 | 2021-09-10 | 北京昭衍生物技术有限公司 | Tim抑制剂及其应用 |
WO2022184930A2 (en) | 2021-03-05 | 2022-09-09 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US337A (en) | 1837-07-31 | Mode of constructing railroad-frogs | ||
US4968A (en) | 1847-02-13 | Spinal elevator | ||
US603A (en) | 1838-02-15 | Improvement in the construction of many-chambered fire-arms | ||
US171A (en) | 1837-04-20 | Machine for washing iron and other ores | ||
US5677A (en) | 1848-07-25 | Improvement in hillside-plows | ||
US5821A (en) | 1848-10-03 | Cream-freezer | ||
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
US6989145B2 (en) | 2000-03-03 | 2006-01-24 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody and antibody fragment |
US7504104B2 (en) | 2001-08-31 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Human CDR-grafted antibody and antibody fragment thereof |
EP4091631A1 (en) | 2002-01-30 | 2022-11-23 | The Brigham and Women's Hospital, Inc. | A tim-3 binding molecule for use in the treatment of a disease |
WO2005057341A2 (en) | 2003-12-02 | 2005-06-23 | Koolspan, Inc. | Automatic hardware-enabled virtual private network system |
KR101562549B1 (ko) | 2005-05-10 | 2015-10-23 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법 |
US20130183288A1 (en) * | 2007-03-28 | 2013-07-18 | Biogen Idec Inc. | Non-fucosylated antibodies |
CA2711370C (en) | 2008-01-15 | 2017-06-13 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
PE20110308A1 (es) | 2008-07-08 | 2011-06-10 | Incyte Corp | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa |
US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
WO2010126066A1 (ja) * | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
AU2010293383B2 (en) | 2009-09-10 | 2014-12-18 | Kyowa Kirin Co., Ltd. | Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4) |
WO2011042065A1 (en) | 2009-10-09 | 2011-04-14 | Daniel Monsch | "momoheli" lifting module and vehicles |
TWI535442B (zh) * | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
PL2581113T3 (pl) * | 2010-06-11 | 2018-11-30 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-tim-3 |
EP2781517B1 (en) | 2011-11-09 | 2017-10-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
AU2013355931B2 (en) * | 2012-12-07 | 2019-03-14 | Kyowa Kirin Co., Ltd. | Anti-FOLR1 antibody |
AU2014265957A1 (en) * | 2013-03-14 | 2015-09-10 | Curadev Pharma Private Ltd. | Inhibitors of the kynurenine pathway |
MX2015017486A (es) | 2013-07-01 | 2016-03-21 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (dio). |
EP3066085B1 (en) * | 2013-11-08 | 2020-05-13 | Incyte Holdings Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
TW201625301A (zh) | 2014-06-06 | 2016-07-16 | Kyowa Hakko Kirin Co Ltd | 藉由folr1標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥 |
-
2016
- 2016-07-14 KR KR1020187001434A patent/KR20180025897A/ko not_active Application Discontinuation
- 2016-07-14 TW TW105122337A patent/TW201713332A/zh unknown
- 2016-07-14 JP JP2018500814A patent/JP2018524361A/ja not_active Ceased
- 2016-07-14 CN CN201680041307.3A patent/CN107847597A/zh active Pending
- 2016-07-14 WO PCT/JP2016/003337 patent/WO2017010106A1/en active Application Filing
- 2016-07-14 EP EP16824090.1A patent/EP3322444A4/en not_active Withdrawn
- 2016-07-14 CA CA2992238A patent/CA2992238A1/en active Pending
- 2016-07-14 EP EP21199914.9A patent/EP3991749A3/en active Pending
- 2016-07-14 US US15/744,322 patent/US20180271861A1/en not_active Abandoned
- 2016-07-14 AU AU2016293667A patent/AU2016293667A1/en not_active Abandoned
-
2018
- 2018-09-14 HK HK18111823.0A patent/HK1252514A1/zh unknown
-
2021
- 2021-09-01 JP JP2021142739A patent/JP7366093B2/ja active Active
- 2021-11-05 US US17/519,990 patent/US20220088011A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7366093B2 (ja) | 2023-10-20 |
EP3991749A2 (en) | 2022-05-04 |
EP3322444A4 (en) | 2019-06-12 |
WO2017010106A1 (en) | 2017-01-19 |
JP2018524361A (ja) | 2018-08-30 |
TW201713332A (zh) | 2017-04-16 |
US20180271861A1 (en) | 2018-09-27 |
CN107847597A (zh) | 2018-03-27 |
JP2021191780A (ja) | 2021-12-16 |
EP3322444A1 (en) | 2018-05-23 |
AU2016293667A1 (en) | 2018-01-04 |
EP3991749A3 (en) | 2022-08-24 |
CA2992238A1 (en) | 2017-01-19 |
KR20180025897A (ko) | 2018-03-09 |
US20220088011A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256383A1 (zh) | 治療劑 | |
HK1248773A1 (zh) | 用於癌症的治療和診斷方法 | |
HK1250376A1 (zh) | 用於癌症的治療和診斷方法 | |
IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
IL249476A0 (en) | Combined treatment with glutaminase inhibitors | |
IL251630A0 (en) | Combined therapy for use in cancer treatment | |
ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
GB201509893D0 (en) | Therapeutic agents | |
HK1252514A1 (zh) | 包含與抗體組合施予的ido抑制劑的腫瘤治療劑 | |
GB201517263D0 (en) | Therapeutic agents | |
EP2968345A4 (en) | DOUBLE MEK / PI3K INHIBITORS AND THERAPEUTIC PROCESSES USING SAME | |
GB201509885D0 (en) | Therapeutic agents | |
GB201509888D0 (en) | Therapeutic agents | |
GB201702160D0 (en) | Inhibitors for use in therapy | |
HUE045185T2 (hu) | Új terápiás vegyület és terápiában történõ alkalmazása | |
GB201513299D0 (en) | Therapeutic agents | |
GB201615844D0 (en) | Agents for use in therapy | |
GB201521767D0 (en) | Therapeutic agents | |
GB201409653D0 (en) | Pyrrolobenzodiazepine therapeutic agents | |
GB201517264D0 (en) | Therapeutic agents | |
SG11201801083UA (en) | Tumor therapeutic agent | |
GB201521755D0 (en) | Therapeutic agents | |
GB201521683D0 (en) | Therapeutic agents | |
GB201520808D0 (en) | Therapeutic agents |